Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other Working Capital Changes (2016 - 2025)

Spero Therapeutics' Other Working Capital Changes history spans 10 years, with the latest figure at $386000.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 77.98% year-over-year to $386000.0; the TTM value through Dec 2025 reached -$277000.0, up 25.14%, while the annual FY2025 figure was -$277000.0, 25.14% up from the prior year.
  • Other Working Capital Changes reached $386000.0 in Q4 2025 per SPRO's latest filing, up from $19000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $3.6 million in Q3 2022 to a low of -$3.6 million in Q2 2022.
  • Average Other Working Capital Changes over 5 years is -$154842.1, with a median of -$141000.0 recorded in 2024.
  • The largest YoY upside for Other Working Capital Changes was 543.8% in 2024 against a maximum downside of 7745.45% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at $2.3 million in 2021, then plummeted by 130.6% to -$690000.0 in 2022, then skyrocketed by 42.75% to -$395000.0 in 2023, then surged by 543.8% to $1.8 million in 2024, then plummeted by 77.98% to $386000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Other Working Capital Changes are $386000.0 (Q4 2025), $19000.0 (Q3 2025), and -$682000.0 (Q2 2025).